These results are in agreement with those published by Antoniou et al. [55], who concluded that the pathogenic mutations in PALB2 confer an absolute risk of 58% for those women with two or more first-degree relatives with BC at 50 years of age, and that the risk is lower for women with no family history of BC. The gene discussed is PALB2; the disease is breast cancer.